share_log

Cortexyme (NASDAQ:CRTX) Versus PharmaCyte Biotech (OTCMKTS:PMCB) Critical Survey

Cortexyme (NASDAQ:CRTX) Versus PharmaCyte Biotech (OTCMKTS:PMCB) Critical Survey

Cortexyme(納斯達克股票代碼:CRTX)對比 Pharmacyte Biotech(OTCMKTS: PMCB)的批判性調查
Defense World ·  2023/04/15 13:53

PharmaCyte Biotech (OTCMKTS:PMCB – Get Rating) and Cortexyme (NASDAQ:CRTX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Pharmacyte Biotech(OTCMKTS: PMCB — 獲取評級)和Cortexyme(納斯達克股票代碼:CRTX — 獲取評級)都是小型醫療公司,但哪隻是優勢股?我們將根據兩家公司的分析師建議、估值、股息、機構所有權、盈利能力、收益和風險對兩家公司進行比較。

Analyst Recommendations

分析師建議

This is a breakdown of recent ratings and price targets for PharmaCyte Biotech and Cortexyme, as reported by MarketBeat.com.

據Marketbeat.com報道,這是Pharmacyte Biotech和Cortexyme最近的評級和目標股價的明細。

Get
獲取
PharmaCyte Biotech
Pharmacyt
alerts:
警報:
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PharmaCyte Biotech 0 0 0 0 N/A
Cortexyme 0 0 0 0 N/A
賣出評級 持有評級 買入評級 強勁的買入評級 評分分數
Pharmacyt 0 0 0 0 不適用
Cortexyme 0 0 0 0 不適用

Earnings & Valuation

收益與估值

This table compares PharmaCyte Biotech and Cortexyme's top-line revenue, earnings per share and valuation.

該表比較了Pharmacyte Biotech和Cortexyme的最高收入、每股收益和估值。

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PharmaCyte Biotech N/A N/A -$4.24 million ($0.26) -11.35
Cortexyme N/A N/A -$89.94 million ($2.97) -0.52
總收入 價格/銷售比率 淨收入 每股收益 市盈率
Pharmacyt 不適用 不適用 -424 萬美元 (0.26 美元) -11.35
Cortexyme 不適用 不適用 -8994 萬美元 (2.97 美元) -0.52

PharmaCyte Biotech is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks.

Pharmacyte Biotech的市盈率低於Cortexyme,這表明它目前是這兩隻股票中更實惠的一隻。

Volatility and Risk

波動率和風險

PharmaCyte Biotech has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.

Pharmacyte Biotech的beta值爲-0.03,這表明其股價的波動性比標準普爾500指數低103%。相比之下,Cortexyme的beta值爲1.4,這表明其股價的波動性比標準普爾500指數高40%。

Institutional and Insider Ownership

機構所有權和內部所有權

33.2% of PharmaCyte Biotech shares are owned by institutional investors. Comparatively, 63.2% of Cortexyme shares are owned by institutional investors. 5.6% of PharmaCyte Biotech shares are owned by insiders. Comparatively, 27.9% of Cortexyme shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pharmacyte Biotech的33.2%的股票由機構投資者持有。相比之下,63.2%的Cortexyme股份由機構投資者持有。5.6%的Pharmacyte Biotech股票由內部人士持有。相比之下,27.9%的Cortexyme股份由內部人士持有。強大的機構所有權表明,對沖基金、捐贈基金和大型基金經理認爲,從長遠來看,公司的表現將超過市場。

Profitability

盈利能力

This table compares PharmaCyte Biotech and Cortexyme's net margins, return on equity and return on assets.

該表比較了Pharmacyte Biotech和Cortexyme的淨利潤率、股本回報率和資產回報率。

Net Margins Return on Equity Return on Assets
PharmaCyte Biotech N/A -6.71% -6.64%
Cortexyme N/A -70.96% -63.53%
淨利潤 股本回報率 資產回報率
Pharmacyt 不適用 -6.71% -6.64%
Cortexyme 不適用 -70.96% -63.53%

About PharmaCyte Biotech

關於 Pharmacyte

(Get Rating)

(獲取評級)

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.

Pharmacyte Biotech, Inc. 是一家臨牀階段的生物技術公司,從事癌症和糖尿病治療的開發和商業化。它專注於一種名爲Cell-in-a-box的基於纖維素的專有活細胞封裝技術,該技術將用作開發無法手術的胰腺癌和其他實體癌腫瘤以及糖尿病治療的平臺。該公司成立於1996年10月28日,總部位於內華達州拉斯維加斯。

About Cortexyme

關於 Cortexyme

(Get Rating)

(獲取評級)

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Cortexyme, Inc. 是一家臨牀階段的生物製藥公司,專注於開發阿爾茨海默氏症和其他退行性疾病的療法。其主要候選藥物是atuzaginstat(COR388),這是一種口服穿腦的小分子牙齦蛋白酶抑制劑,正在進行II/III期臨牀試驗,用於輕度至中度阿爾茨海默病患者,也用於治療口腔鱗狀細胞癌、牙周炎和冠狀病毒感染。該公司成立於2012年,總部位於加利福尼亞州南舊金山。

Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Pharmacyte 生物技術日報的新聞和評級 -在下面輸入您的電子郵件地址,即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Pharmacyte Biotech及相關公司的最新新聞和分析師評級的簡明每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論